natgillin/translations-raw huggingface dataset:
Forskelle i vedvarende virologisk respons (SVR)baseret på behandlingsvarighed, demografiske karakteristika og bedste respons ved tidligere behandling er vist i tabel 18.
Differences in sustained virological response (SVR) based on treatment duration, demographics and best responses to previous treatment are displayed in Table 18.
Forskelle mellem grupper a (95% CI)
Between group difference a ( 95% CI)
Forskelle*
Differences
Forskellen blev opretholdt fra dag 7 til og med måned 6 (figur 1).
The difference was maintained from Day 7 through Month 6 (Figure 1).
Forskellen er 2 enheder
Difference is 2 units.
Forskellen er på mere end 2 enheder OptiSet er beskadiget.
OptiSet is damaged or is not working properly.
Forskellen er på mere end 2 enheder: OptiSet er beskadiget, brug en ny OptiSet.
Difference is more than 2 units.
Forskellen er på mere end 2 enheder: OptiSet er beskadiget, brug en ny OptiSet. injicere det der er tilbage i denne pen og færdiggøre din dosis med en ny OptiSet.
Difference is more than 2 units OptiSet is damaged, use a new OptiSet. inject the amount indicated on the injection button from this OptiSet and then inject the remaining dose using a new OptiSet, or inject the entire dose using a new OptiSet.
Forskellen i andelen af patienter, der bibeholdte < 400 kopier/ml ved uge 48 var hovedsageligt påvirket af det højere antal seponeringer i behandlingsgruppen med tenofovirdisoproxilfumarat.
The difference in the proportion of patients who maintained < 400 copies/ml at week 48 was mainly influenced by the higher number of discontinuations in the tenofovir disoproxil fumarate treatment group.
Forskellen i behandling mellem lumacaftor 400 mg hver 12. time alene og placebo evalueret som en gennemsnitlig ændring i ppFEV1 var -4,6 procentpoint (95% CI: -9,6, 0,4) fra baseline til dag 28, 4,2 procentpoint (95% CI: -1,3, 9,7) fra baseline til dag 56 og 7,7 procentpoint (95% CI: 2,6, 12,8, statistisk signifikant) fra dag 28 til dag 56 (efter tilføjelse af ivacaftor til lumacaftormonoterapi).
The treatment difference between lumacaftor 400 mg q12h alone and placebo evaluated as mean absolute change in ppFEV1 was -4.6 percentage points (95% CI: -9.6, 0.4) from baseline to Day 28, 4.2 percentage points (95% CI: –1.3, 9.7) from baseline to Day 56, and 7.7 percentage points (95% CI: 2.6, 12.8; statistically significant) from Day 28 to Day 56 (following the addition of ivacaftor to lumacaftor monotherapy).
Forskellen i behandlingen i denne undergruppe svarede til den observerede forskel hos patienter med ppFEV1 ≥40.
The treatment difference in this subgroup was comparable to that observed in patients with ppFEV1 ≥40.
Forskellen i biotilgængeligheden er mindre tydelig ved steady-state- indgivelse til nyretransplanterede patienter, og terapeutisk ækvivalens er påvist i et randomiseret forsøg af 477 patienter.
The difference in bioavailability was less marked upon steady-state administration to renal transplant recipients, and therapeutic equivalence has been demonstrated in a randomised study of 477 patients.
Forskellen i DDR mellem Imlygic og GM-CSF i ITT-populationen var statistisk signifikant (se Tabel 4) til Imlygics fordel.
The difference in DRR between Imlygic and GM-CSF in the ITT population was statistically significant (see Table 4) in favour of Imlygic.
Forskellen i den samlede overlevelse viste en stærk klinisk forskel (p=0,029, log rank test stratificeret ved center): overlevelsesrater på 53 måneder var 80,9 % for patienter i R-CVP-gruppen i forhold til 71,1 % for patienter i CVP-gruppen.
The difference between the treatment groups with respect to overall survival showed a significant clinical difference (p=0.029, log-rank test stratified by centre): survival rates at 53 months were 80.9% for patients in the R-CVP group compared to 71.1 % for patients in the CVP group
Forskellen i forbedring i den generelle subskala-score for synsevne var statistisk signifikante (6,1 Jetrea vs.
The difference for improvement in the general vision sub-scale score was statistically significant (6.1 JETREA vs.
Forskellen i forekomsten af smerte var 9,9 % (95% konfidensinterval 4,0-15,8 %) mellem de Velactis-behandlede køer og de placebo-behandlede dyr.
The difference in occurrence of pain was 9.9% (95% confidence interval 4-15.8%) between the Velactis treated cows compared to placebo treated animals.
Forskellen i gennemsnitlig LS-ændring fra baseline til dag 21 i total YMRS- score mellem asenapin 10 mg to gange dagligt og placebo var -3,0 point (95 % CI [-5,6; -0,4]; p = 0,0244).
The difference in LS mean change from baseline to Day 21 in the Y-MRS total score between asenapine 10 mg BID and placebo was -3.0 points (95 % CI [-5.6, -0.4]; p-value = 0.0244).
Forskellen i HbeAg-serokonversionshastighed (HBeAg og HBV DNA-tab ved HbeAb-detektion) mellem placebo og lamivudin var ikke statistisk signifikant i denne population (forekomsten efter 1 år var 13 % (12/95) for placebo versus 22 % (42/191) for lamivudin; p=0,057).
The difference in the HBeAg seroconversion rates (HBeAg and HBV DNA loss with HBeAb detection) between placebo and lamivudine was not statistically significant in this population (rates after one year were 13 % (12/95) for placebo versus 22 % (42/191) for lamivudine; p=0.057).
Forskellen i kropsvægt er henholdsvis 26 og 23 %.
The body weight normalized difference is 26 and 23%, respectively.
Forskellen i procent af nye intramammære infektioner i goldperioden mellem dyr behandlet med Velactis eller med placebo var 5,5 % (95 % konfidensinterval 0,5-10,4 %).
The difference percentage of new intramammary infections during the dry period between Velactis treated animals and the placebo group was 5.5% (95% confidence interval 0.5-10.4%).
Forskellen i responsrate ved uge 48 er 1 % (95 % konfidensinterval 3 % til 6 %) ved hjælp af normal tilnærmelse.
The difference of response rate at Week 48 is 1% (95% confidence interval -3% to 6%) using normal approximation.
Forskellen i smerternes intensitet blev målt af patienterne, som vurderede deres smerter på en skala fra 0 til 10.
The change in pain severity was measured by the patients ranking their pain on a scale from 0 to 10.
Forskellen i SVR-rater (95% konfidensinterval) mellem T12/PR- og Pbo/PR-gruppen var 33 (26, 39).
The difference in SVR rates (95% confidence interval) between the T12/PR and Pbo/PR groups was 33 (26, 39).
Forskellen i tid til lukning af et sår blev sat til 0 for serien af fotos bedømt som "ikke-evaluerbare".
Difference in time to wound closure was set to 0 for photo series rated as ‘not evaluable’.
Forskellen i tiden til fuldstændig sårlukning er hovedsageligt relateret til sårplejestrategien, som lægen anvender, hvor et forsøg på at minimere transplantation og give tid til spontan epitelialisering af sårområder, der stadig har dermis, kan forlænge tiden til første autotransplantation (tid til autotransplantation: NexoBrid: 14,7 dage vs.
The difference in time to complete wound closure is mainly related to the wound care strategy applied by the physician, where an attempt to minimise grafting and allow for spontaneous epithelialisation of the wound areas that still have dermis may prolong time to first autograft (time to autograft: NexoBrid: 14.7 days vs.
Forskellen mellem 20 mg- og placebo-gruppen, i den gennemsnitlige ændring af kropsvægt, var 3,8 kg (CI95% -5,0, -2,6 p < 0,001).
The difference in mean body weight change between the 20 mg and placebo groups was 3.8 kg (CI95% -5.0, -2.6 p< 0.001).
Forskellen mellem 20 mg- og placebo-gruppen, i den gennemsnitlige ændring af kropsvægt, var 3,8 kg (CI95% -5,0, -2,6 p < 0,001).
The difference in mean body weight change between the 20 mg and placebo groups was 3.8 kg (CI95% -5.0, -2.6 p<0.001).
Forskellen mellem Nordimet og Lantarel FS er, at Nordimet fås i flere forskellige styrker.
The difference between Nordimet and Lantarel FS is that Nordimet is available in more strengths.
Forskellen på AUC og C-maks for oxybutynin og den aktive metabolit, N-desethyloxybutynin, efter transdermal indgivelse af Kentera på enten mave, balder eller hofte er ikke klinisk relevant.
The difference in AUC and Cmax of oxybutynin and the active metabolite N-desethyloxybutynin following transdermal administration of Kentera on either the abdomen, buttocks or hip is not clinically relevant.
Forskellen skyldtes hovedsageligt en højere procentdel af patienter i placebogruppen, som oplevede 3 eller flere episoder med hypoglykæmi (9,1 versus 19,8%).
The difference was mainly due to a higher percentage of patients in the placebo group experiencing 3 or more episodes of hypoglycaemia (9.1 vs.
Forskellen skyldtes hovedsageligt en højere procentdel af patienter i placebogruppen, som oplevede 3 eller flere episoder med hypoglykæmi (9,4 versus 19,1%).
The difference was mainly due to a higher percentage of patients in the placebo group experiencing 3 or more episodes of hypoglycaemia (9.4 vs.
Forskellen skyldtes udfaldet i gruppen af orlistatbehandlede patienter med ≥ 5 % vægttab efter 12 ugers behandling, hvilket svarede til 19 % af den initiale population.
The difference was driven by the outcome in the group of patients with ≥ 5 % weight loss after 12 weeks of treatment with orlistat representing 19 % of the initial population.
Forskellen var ikke statistisk signifikant, men der var en tendens til forbedring af overlevelse med 15 % reduktion i risikoen for død hos forsøgspersoner i Dacogen- gruppen (figur 1).
The difference did not reach statistical significance, however, there was a trend for improvement in survival with a 15% reduction in the risk of death for subjects in the Dacogen arm (Figure 1).
Forskellen var statistisk signifikant (forskel -13,3 % CI95 – 16,5; -10,2 % p < 0,001).
The difference was statistically significant (Difference -13.3% CI95% -16.5; -10.2% p< 0.001).
Forskellen var statistisk signifikant (forskel -13,3 % CI95 – 16,5; -10,2 % p < 0,001).
The difference was statistically significant (Difference -13.3% CI95% -16.5; -10.2% p<0.001).
Forskellen var statistisk signifikant med anvendelse af en chi2 test (p=0,015).
The difference was statistically significant using the chi-square test (p=0.015).
Forskellene anses ikke for at være klinisk relevante, da Xultophy blev initieret og titreret efter den enkelte patients blodglucosemål.
The differences are considered of no clinical relevance since Xultophy is initiated and titrated according to the individual patient’s blood glucose targets.
Forskellene i forhold til de voksne og andre specielle faktorer omtales i følgende afsnit.
Differences from adults and other special considerations are discussed in the following paragraphs.
Forskellene mellem de 2 grupper var statistisk signifikante (p<0,05).
Differences between the 2 groups were statistically significant (p0.05).
Forskellene mellem de 2 grupper var statistisk signifikante (p0,05). a Begrænset til kvinder med induceret ovulation (follitropin beta, n = 76; u-FSH, n = 42).
Differences between the 2 groups were statistically significant (p0.05). a Restricted to women with ovulation induced (follitropin beta, n = 76; u-FSH, n = 42).
Forskellene mellem de 2 grupper var statistisk signifikante (p0,05). a Begrænset til kvinder med induceret ovulation (Puregon, n = 76; u-FSH, n = 42).
Differences between the 2 groups were statistically significant (p0.05). a Restricted to women with ovulation induced (Puregon, n = 76; u-FSH, n = 42).
Forskellene mellem de to arme indeholdende nivolumab blev deskriptivt evalueret.
The differences between the two nivolumab- containing groups were evaluated descriptively.
Forskellene mellem IRC’er og investigatorens vurderinger af respons var en konsekvens af kriterierne i den internationale arbejdsgruppe (International Working Group, IWG), som kræver forbedring i perifere blodtællinger og opretholdelse af disse forbedringer i mindst 56 dage.
The differences between the IRC and investigator assessments of response were a consequence of the International Working Group (IWG) criteria requiring improvement in peripheral blood counts and maintenance of these improvements for a minimum of 56 days.
Forskelle†
Difference
Forskellige betingelser til administration
Different conditions of administration
Forskellige doser af Volibris (2,5, 5 og 10 mg) blev sammenlignet med placebo (en virkningsløs behandling) i to hovedundersøgelser, der omfattede i alt 394 patienter med PAH, hvoraf de fleste havde klasse II- eller klasse III-sygdom, som var af ukendt årsag eller forårsaget af bindevævssygdom.
Various doses of Volibris (2.5, 5 and 10 mg) have been compared with placebo (a dummy treatment) in two main studies involving a total of 394 patients with PAH, most of whom had class II or III disease that was of unknown cause or caused by connective tissue disease.
Forskellige doseringsregime
Different posology regimen
Forskellige fingre,
Different Fingers,
Forskellige fingre, Begge MP’er (n=244)
Different Fingers, Both MPs (n=244)
Forskellige fingre, begge PIP’er (n=72)
Different Fingers, Both PIPs (n=72)
Forskellige foretrukne MedDRA-termer, som blev betragtet som værende klinisk ens, er grupperet i en enkelt term.
Different MedDRA preferred terms that were considered clinically similar have been grouped into a single term.
Forskellige former for udslæt
Different types of rash
Forskellige innovationer har bidraget til at forbedre resultaterne ved denne indikation: teknik til tidlig diagnose af Epstein-Bar (EBV) og CMV-infektioner, knoglemarvsforøgelse, samtidig brug af interleukin 2- antagonisten daclizumab, lavere initiale doser af tacrolimus med dalkoncentrationer på 10-15 ng/ml og senest bestråling af allotransplantat.
A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time.
Forskellige neoplasier, omfattende brystcancer, keratoacanthom i huden og basalcelleadenom, fandtes i en undersøgelse omfattende 6-cycli på rotter, mens der ikke sås tumorer eller præneoplastiske forandringer i undersøgelser på hunde.
A variety of neoplasms, including mammary carcinomas, keratocanthoma of the skin and basal cell adenoma were observed in the 6- cycle rat study while no tumours or pre-neoplastic changes were evident in dog studies.
forskellige steroider - såsom dexamethason, ethinylestradiol, fluticason
various steroids - such as dexamethasone, ethinyl estradiol, fluticasone
forskellige steroider – såsom dexamethason, ethinylestradiol, fluticason,
various steroids - such as dexamethasone, ethinyl estradiol, fluticasone
Forskellige stimulationsregimer kan benyttes.
Various stimulation protocols are applied.
Forskellige typer udslæt
Different types of rash
Forskellige, foretrukne MedDRA-termer, der blev anset som klinisk ens, er blevet samlet i en enkelt term. b inkl. defekt i corneale epithelium, corneaerosion, cornealæsion, corneaopacitet, corneaperforation, keratitis, keratitis punctata, ulcerativ keratitis, limbal stamcelle-mangel, nedsat visuel skarphed, synsforringelse, sløret syn.
Different MedDRA preferred terms that were considered clinically similar have been grouped into a single term. b incl corneal epithelium defect, corneal erosion, corneal lesion, corneal opacity, corneal perforation, keratitis, punctate keratitis, ulcerative keratitis, limbal stem cell deficiency visual acuity reduced, visual impairment, vision blurred.
Forskellige, foretrukne MedDRA-termer, der blev anset som klinisk ens, er blevet samlet i en enkelt term. b inkl. defekt i corneale epithelium, corneaerosion, cornealæsion, corneaopacitet, corneaperforation, keratitis, keratitis punctata, ulcerativ keratitis, limbal stamcelle-mangel, nedsat visuel skarphed, synsforringelse, sløret syn.
Different MedDRA preferred terms that were considered clinically similar have been grouped into a single term. b incl corneal epithelium defect, corneal erosion, corneal lesion, corneal opacity, corneal perforation, keratitis, punctate keratitis, ulcerative keratitis, limbal stem cell deficiency, visual acuity reduced, visual impairment, vision blurred.
Forskernes globale vurderinger af effekt viste også signifikant forbedring.
Investigator’s global assessments of efficacy also showed significant improvement.
Forskning har vist en øget risiko for medfødte misdannelser hos børn af kvinder, der tager medicin mod epilepsi.
Research has shown an increased risk of birth defects in children of women taking anti-epileptic medicines.
Forskudt caput femoralis epifyser og udvikling af skoliose kan forekomme hos patienter, som oplever hurtig vækst.
Slipped capital femoral epiphysis and progression of scoliosis can occur in patients who experience rapid growth.
Forskydning af det indvendige væv af livmoderhalsen (ektropion) fundet ved helbredsundersøgelse
Cervical erosion found on medical examination
Forskydning af doseringen af hydrochlorthiazid og anionbytter således, at hydrochlorthiazid gives mindst 4 timer før eller 4-6 timer efter indgift af anionbytter kan dog muligvis minimere  interaktionen.
However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins would potentially minimise the interaction.
Forskydning af doseringen af hydrochlorthiazid og anionbytter således, at hydrochlorthiazid gives mindst 4 timer før eller 4-6 timer efter indgift af anionbytter kan dog muligvis minimere interaktionen.
However, staggering the dosage of hydrochlorothiazide and resin such that hydrochlorothiazide is administered at least 4 hours before or 4-6 hours after the administration of resins  would potentially minimise the interaction.
Forslag til fortynding baseret på den anbefalede dosering af 52 mg/m2/dag clofarabin
Suggested dilution schedule based on the recommended dosage of 52 mg/m2/day clofarabine
forsnævring af arterierne (systemisk perifer arteriel sygdom), hjertesygdom (for alvorlige hjerteproblemer, se ovenfor under “Tag ikke Ceplene”), tidligere autoimmun sygdom (en sygdom, hvor immunsystemet angriber kroppens egne celler eller væv, såsom systemisk lupus, rheumatoid artritis, inflammatorisk tarmsygdom eller psoriasis).
narrowing of the arteries (systemic peripheral arterial disease), heart disease (for severe heart problems see above “Do not use Ceplene”), a history of auto-immune disease (a disease where the immune system attacks the body’s own cells or tissues, such as systemic lupus, rheumatoid arthritis, inflammatory bowel disease or psoriasis).
Forsnævring af blodkar i hjertet
Narrowing of the blood vessels in the heart
Forsnævring af blodkarrene med nedsat blodgennemstrømning til følge
Narrowing of the blood vessels causing blood flow to be decreased
Forsnævring af blodkarrene til den ene eller begge nyrer (nyre-arteriestenose)
Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
Forsnævring af blodkarrene til den ene eller begge nyrer (nyre-arteriestenose).
Renal artery stenosis (narrowing of the blood vessels to one or both kidneys).
forsnævring af de blodkar, der forsyner hjertet med blod og ilt
Narrowing of the blood vessels that supply blood and oxygen to the heart
forsnævring af de blodkar, der forsyner hjertet med blod og ilt
Narrowing of the blood vessels that supply blood and oxygen to the heart;
Forsnævring af hjertets legemspulsåre, aorta (aortastenose).
Narrowing of the aorta (aortic stenosis).
forsnævring af pulsårer i hjernen
narrowing of the arteries in the brain
forsnævring eller blokering af tårekanalen
narrowing or blockage of tear duct (lacrimal duct stenosis)
forsnævring eller blokering af tårekanalen,
narrowing or blockage of tear duct (lacrimal duct stenosis)
FORSTEO 20 mikrogram/80 mikroliter injektionsvæske, opløsning, i fyldt pen Teriparatid
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen Teriparatide
FORSTEO 20 mikrogram/80 mikroliter injektionsvæske, opløsning, i fyldt pen.
FORSTEO 20 micrograms/80 microliters solution for injection in pre-filled pen
FORSTEO 20 mikrogram/80 mikroliter, injektionsvæske Teriparatid
FORSTEO 20 micrograms/80 microliters, injection Teriparatide
Forsteo anvendes til behandling af osteoporose (en sygdom, der gør knoglerne skøre) i følgende grupper: kvinder efter overgangsalderen.
Forsteo is used for the treatment of osteoporosis (a disease that makes bones fragile) in the following groups: women who have been through the menopause.
FORSTEO er en farveløs og klar opløsning.
FORSTEO is a colourless and clear solution.
FORSTEO er kontraindiceret under graviditet (se punkt 4.3).
FORSTEO is contraindicated for use during pregnancy (see section 4.3).
FORSTEO er kontraindiceret ved amning.
FORSTEO is contraindicated for use during breast-feeding.
FORSTEO frarådes til brug af blinde eller synshæmmede uden hjælp af en person, der er instrueret i rigtig brug af pennen.
The FORSTEO is not recommended for use by the blind or visually impaired persons without the assistance of a person trained in the proper use of the device.
FORSTEO indeholder medicin til 28 dage.
The FORSTEO contains 28 days of medicine.
Forsteo kan anvendes i op til to år.
Forsteo can be used for up to two years.
FORSTEO kan give forøget indhold af kalk (calcium) i blodet eller urinen.
FORSTEO may cause an increase in the amount of calcium in your blood or urine.
FORSTEO kan medføre mindre stigninger i udskillelsen af calcium i urinen, men forekomsten af hypercalcuri viste sig i de kliniske forsøg ikke at adskille sig fra den, som observeredes hos placebo- behandlede patienter.
FORSTEO may cause small increases in urinary calcium excretion, but the incidence of hypercalciuria did not differ from that in the placebo-treated patients in clinical trials.
FORSTEO leveres i en fyldt pen.
FORSTEO is supplied in a pre-filled pen.
FORSTEO må ikke anvendes, hvis opløsningen er uklar, farvet eller indeholder partikler.
Do not use FORSTEO if solid particles appear or if the solution is cloudy or coloured.
FORSTEO må ikke bruges til børn og unge (under 18 år).
FORSTEO should not be used in children and adolescents (less than 18 years).
FORSTEO må ikke bruges, hvis opløsningen er uklar, farvet eller indeholder partikler.
FORSTEO should not be used if the solution is cloudy, coloured or contains particles.
FORSTEO skal administreres en gang dagligt ved subkutan injektion i lår eller abdomen.
FORSTEO should be administered once daily by subcutaneous injection in the thigh or abdomen.
FORSTEO skal opbevares i køleskab (2 °C – 8 °C) hele tiden.
FORSTEO should be stored in a refrigerator (2C to 8C) at all times.
FORSTEO, 20 mikrogram (µg)/80 mikroliter injektionsvæske, opløsning, i fyldt pen.
FORSTEO 20 micrograms (µg)/ 80 microlitres solution for injection, in pre-filled pen Instructions for use
FORSTEO-pennen (se
FORSTEO (see
FORSTEO-pennen ser ud til at være beskadiget.
The FORSTEO appears damaged
FORSTEO-pennens opbygning*
Forsteo parts
FORSTEOs sikkerhed og virkning hos børn og unge under 18 år er ikke klarlagt.
The safety and efficacy of FORSTEO in children and adolescents less than 18 years has not been established.
Forstoppelse
constipation
forstoppelse
constipation,
Forstoppelse
Constipation;
Forstoppelse
Dyspepsia
Forstoppelse
Gastrointestinal disorders
Forstoppelse
Haemoglobin decreased
forstoppelse
indigestion,
forstoppelse (besvær med afføring)
constipation (difficulty passing stools)
forstoppelse (besvær med afføring) træthed
constipation (difficulty passing stools) tiredness.
forstoppelse (konstipation)
Constipation
Forstoppelse Diaré Opkastning Dyspepsi Flatulens
Constipation Diarrhoea Vomiting Dyspepsia Flatulence
forstoppelse dyspepsi
constipation dyspepsia
Forstoppelse Dyspepsi Diaré
Constipation Dyspepsia Diarrhoea
Forstoppelse Dyspepsi Kvalme
Constipation Dyspepsia Nausea Salivary hypersecretion Vomiting
Forstoppelse Dyspepsi Kvalme Øget spytsekretion Opkastning
Constipation Dyspepsia Nausea Salivary hypersecretion Vomiting
Forstoppelse eller fordøjelsesbesvær
constipation or indigestion
forstoppelse endetarmsgener.
constipation rectal discomfort
forstoppelse hudkløe
constipation itchy skin